The toxicity of isoniazid chemoprophylaxis was assessed in 83 health care workers (HCWs) receiving a 6-month course, in whom clinical toxicity and liver function were monitored. Thirty-four HCWs (41%) developed an adverse event; in 26 (76%), toxicity was sufficiently severe to require cessation of treatment. Of the total, liver function test abnormalities (serum alanine transaminase levels more than two times normal) were evident in 14 subjects, with 8 requiring cessation of therapy. Other symptoms reported included malaise, nausea with associated anorexia, arthralgia, and rash. Mean time to development of symptoms was 3 weeks (range, 0.5 -6 weeks), with the mean age of those with toxicity not differing significantly from those without (38 vs. 39 years). The high rate of toxicity seen in this study is sufficiently notable that we advocate the use of monthly liver function testing and frequent review in those receiving isoniazid prophylactic therapy.
Tuberculosis is a well-recognized occupational risk for by chest radiography and were seen by a physician for further counseling. health care workers (HCWs) [1] . Although rates of tuberculosis declined steadily since the 1950s, HIV infection and multidrugIsoniazid therapy was discussed with each subject attending for physician follow-up. Subjects were informed of potential resistant strains of Mycobacterium tuberculosis have resulted in a resurgence in the last decade, with nosocomial transmission benefits and toxicities of isoniazid and were encouraged to make individual decisions about whether to commence therapy. of tuberculosis to HCWs recently reported [2] . Effective infection control measures can greatly decrease nosocomial transPersons with a history of heavy alcohol intake or chronic liver disease were not offered isoniazid prophylaxis. Similarly, all mission, but this alone will not eliminate the risk for HCWs. Therefore, other means of reducing occupationally acquired subjects were counseled to minimize their alcohol intake should they wish to proceed with isoniazid prophylaxis. Specific serotuberculosis remain important.
Isoniazid (isonicotinic acid hydrazide) has been shown to be logic studies for hepatitis B and C viruses and HIV were done if risk factors for acquisition of these viruses were identified. effective in preventing the development of active disease among asymptomatic, infected persons by 60% -95% [3, 4] .
Those HCWs considering the commencement of isoniazid had a baseline serum liver function test (LFT) done to assess Despite the benefits of preventive therapy, isoniazid is not widely applied because of missed opportunity, fears of toxicity, the existence of underlying hepatic inflammation. If LFT results were normal, a 6-month course of isoniazid, 300 mg/day, and and poor adherence [5] . To assess the toxicity of isoniazid, we prospectively monitored HCWs receiving isoniazid chemopropyridoxine, 25 mg/day, was prescribed. Subsequently, further LFTs were done at monthly intervals. If these were abnormal, phylaxis in a public hospital undergoing a comprehensive tuberculin skin-testing program.
serologic studies for hepatitis A, B, and C viruses were done to exclude a viral cause of liver dysfunction. At each monthly clinical review, information was obtained regarding the HCWs' Methods adherence with isoniazid therapy and whether they had noted any symptoms, including those that could be potentially isoniaAs a part of an Occupational Health and Safety program, zid-associated. HCWs were offered a tuberculin skin test (TST) according to Australian guidelines [6] . A strong positive reaction was defined as §15 mm in subjects with prior bacille Calmette-Guérin Results vaccination and §10 mm in those without such a history [7] . All HCWs with strongly positive TST results were screened A total of 878 HCWs had TSTs done, 89% of whom had a definite history of bacille Calmette-Guérin vaccination. Overall, 299 (34%) of 878 had a strong positive reaction. Of these, 291 with a history of bacille Calmette-Guérin vaccination had symptoms. Although isoniazid-induced asymptomatic hepatitis † For those HCWs ceasing therapy. ‡ Peak alanine aminotransferase readings were noted after mean of 6 weeks has been reported in up to 10% -20% of subjects and overt (range, 4 -8 weeks). hepatitis in 1%, its incidence is generally reported to be agerelated, particularly in those ú35 years old [8] . Our findings reveal a greater incidence of toxicity than these historical data, and the notable lack of symptoms among those HCWs with lous disease. This latter subject, although asymptomatic, began to receive standard antituberculous therapy as prescribed by the most severe hepatitis reinforces the importance of regular monitoring of hepatic function in all isoniazid-treated persons. the managing physician.
In this perceived outbreak setting, uptake of isoniazid was Less severe symptoms, however, accounted for more treatment withdrawals. Importantly, symptoms often regarded as relatively high, with 83 (28%) of the 299 TST-positive HCWs commencing isoniazid therapy. The mean age of these subjects insignificant (e.g., malaise, nausea, arthralgia, and myalgia) were prominent in our study population and were considered was 38 years (median, 39 years; range, 25 -56 years), and 73 were female. During the 6-month treatment period, side effects to be of sufficient severity to require isoniazid cessation in the majority of subjects, despite patients' motivation to complete considered to be isoniazid-related were reported by 34 (41%) of 83 HCWs, of whom 26 had side effects that were considered treatment.
The reasons for the high rate of reported side effects remain sufficiently severe to require cessation of therapy (table 1). All symptoms resolved promptly on cessation of isoniazid. In uncertain and are probably multifactorial. Unfortunately, the lack of a control group in this study limits the certainty with addition, four subjects were nonadherent for reasons not related to toxicity. Thus, overall, 30 (36%) of 83 HCWs ceased isoniawhich all reported adverse reactions can be directly attributed to isoniazid, although this seems very likely. Nevertheless, this zid before the completion of therapy, 26 (87%) of 30 because of toxicity. rate of toxicity is somewhat higher than the 11.4% reported by Camins et al. [9] in their retrospective study of 105 HCWs Alteration of serum alanine transaminase levels more than twofold above normal was noted in 14 subjects (17%) receiving receiving isoniazid. In comparison, the higher rate of toxicity that we noted may have been due to the prospective nature of isoniazid. Five of these (6% overall) had serum alanine aminotransferase levels more than fivefold above normal and were our study in which liver function and clinical progress were monitored prospectively at monthly intervals. advised to cease therapy. These five HCWs were all female (mean age, 38 years; range, 36 -41 years), and none had more However, the fact that a reasonably large number of HCWs considered their symptoms to be of sufficient severity to cease than mild symptoms. Among these five HCWs, abnormal LFTs were first noted after 4 weeks of therapy. However, peak serum treatment suggests that other factors may also be involved. The predominance of females, most of them of child-bearing age, alanine aminotransferase levels of 385, 250, 305, 350, and 1,805 U/L (normal, õ50 U/L) occurred 8, 6, 5, 7, and 4 weeks, in our study population suggests the possibility of hormonal influences on isoniazid toxicity. Unfortunately, we did not colrespectively, after they commenced receiving isoniazid. In addition to these five HCWs, a further three with abnormal LFTs lect data on menstrual cycles or the use of the oral contraceptive pill in our cohort. Finally, we cannot exclude some overreportalso ceased treatment because of symptoms considered to be related to isoniazid. Six of the 14 HCWs were asymptomatic ing of subjective symptoms among HCWs who were working closely together and discussing their problems with each other. and continued isoniazid without incident, despite having mildly abnormal LFTs. No HCW developed clinical jaundice. No subHowever, the rate of objective adverse events argues against this constituting the main explanation. jects with liver function abnormalities had serologic evidence / 9c64$$ap60 03-19-99 05:18:01 cida UC: CID
